GET DAILY SIGNALSSpectral AI (MDAI) and the Path to a $5.00 Target: What a +227% Move Would Require
Key Takeaways
- The central $5.00 target is the rounded arithmetic mean of three verified analyst price targets ($4.00, $4.00 and $6.25), which average roughly $4.75.
- With the stock near $1.53, reaching $5.00 would require a gain of about 227%, a very large move by any standard.
- Published targets span a wide $4.00 to $6.25 range, reflecting sharp disagreement over how quickly the company can convert regulatory clearance into commercial sales.
- The strongest support is Spectral AI's May 2026 U.S. FDA De Novo clearance for its DeepView System, plus non-dilutive government funding.
- The biggest risks are a pre-commercial revenue base, persistent losses and cash burn, and the potential for further shareholder dilution.
- Spectral AI, Inc. (NASDAQ: MDAI) is a micro-cap medical-AI company whose DeepView platform predicts wound-healing potential for burns and other wounds.
- For more detail on the company, see its Major News and Today's Price Move pages, or explore its Forecast and Earnings pages.
- Interested in automated market analysis? Explore Trending AI Robots for data-driven trading ideas.
Analyst Price Targets and the Current Consensus
MDAI carries unusually thin sell-side coverage, with roughly three analysts publishing targets and none assigning a Hold or Sell rating. That leaves an all-Buy stance that is typical yet noticeably one-sided. The three targets I reviewed are $4.00 from Northland Securities (maintained in August 2026), $4.00 from BTIG (raised from $3.00 in May 2026), and a higher $6.25 at the top of the range. This produces a $4.00–$6.25 band and an arithmetic mean near $4.75, which rounds to the $5.00 central figure used here. The roughly 56% spread between low and high targets is wide and points to real uncertainty about commercialization speed rather than a settled view. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Because every target sits well above the current price, these figures read best as longer-term, execution-dependent estimates.
Current Market Position and the Scale of the Target
The latest share price sits near $1.53, inside a 52-week range of $1.18 to $2.97 and far below the September 2023 peak near $19.50. Reaching the $5.00 target from here would require an advance of about 227%, a substantial move even by growth-stock standards. Even the lowest published target of $4.00 implies upside above 160%. That gap reflects the market pricing in execution risk after the May 2026 FDA De Novo clearance for the DeepView System’s burn indication. The shares have not re-rated sharply, which suggests investors remain cautious about a company that spent most of its history in development mode. A sustained move higher would likely need evidence of installed systems, recurring contracts, and Medicare reimbursement progress.
Key Supports That Could Drive Progress
The FDA clearance itself is the clearest catalyst, shifting DeepView from a development program to an authorized commercial product in the United States. The company is pursuing a New Technology Add-On Payment application for Medicare reimbursement, submitted in October 2026, and has started a clinical study aimed at label expansion to burns of the head, hands, and feet. Funding adds another layer of support. Spectral AI has received roughly $282.5 million in government awards since 2013, largely from BARDA, including a $31.7 million award noted in early 2026, along with Department of Defense backing for a handheld module. This non-dilutive capital has helped limit reliance on equity raises. Management has guided fiscal 2026 revenue near $18.5 million, with an inflection framed for 2027 once commercialization gains traction.
Risks That Could Keep the Target Out of Reach
The main hurdle remains the pre-commercial nature of the business. Most reported revenue still comes from reimbursed research-and-development funding rather than product sales, and second-quarter 2026 revenue of about $3.5 million declined roughly 30% year over year. The company posted a net loss near $4.2 million for the quarter and remains unprofitable. Cash stood at roughly $14.0 million at June 30, 2026, against about $16.3 million of debt, with negative equity and ongoing cash burn. That environment raises the prospect of further financing that could dilute shareholders. As a micro-cap with about 32 million shares and a market value near $50 million, the stock trades thinly and remains volatile while it works to demonstrate hospital adoption of the novel AI imaging device. From what I see, these balance-sheet dynamics are worth watching closely.
Technical Levels and Market Structure
MDAI trades below both its 20-day and 200-day moving averages, consistent with a lingering downtrend even after the FDA milestone. The 52-week low near $1.18 offers key support, with $1.00 acting as a nearby psychological floor. On the upside, the 52-week high near $2.97 is the first major resistance that would need to be reclaimed, while $5.00 itself sits well above current market structure as a longer-term psychological level.
Time Horizon and Items to Monitor
Analyst targets generally reflect a roughly 12-month research horizon, though timing for an early-stage name is less precise. The next earnings release is expected in mid-November 2026. The most relevant items for the target are early commercial revenue signs, the Medicare NTAP decision, progress on the head/hands/feet label-expansion study, BARDA contract execution, and any new financing activity. Revisions to the limited analyst coverage will also matter given how much the wide target range rests on assumptions rather than reported sales. I’m watching this closely as those milestones approach.
Using AI Daily Buy/Sell Signals for Ongoing Monitoring
Tickeron’s AI Daily Buy/Sell Signals apply artificial intelligence to track thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like MDAI, the tool provides an efficient way to spot opportunities and track trend changes without relying solely on manual chart review. I find it helpful for keeping an eye on names that move quickly on regulatory or funding news.
Final Assessment
Whether MDAI can reach the $5.00 level depends less on valuation math than on execution. The rounded $5.00 target, derived from the $4.00–$6.25 analyst range averaging about $4.75, implies a move of roughly 227% from the current price near $1.53. That is a large gain that assumes successful commercialization. The bull case centers on FDA clearance, non-dilutive government funding, and reimbursement progress, while the bear case rests on a pre-commercial revenue base, ongoing losses, and dilution risk. With limited analyst coverage and a wide target spread, investors should follow the next earnings report and early commercial signals closely. No price outcome is guaranteed.
Exploring Tickeron AI Tools for Research
In my own work, I often turn to Tickeron’s suite of AI tools when reviewing names like this one. The AI Daily Buy/Sell Signals platform stands out for its ability to surface real-time signals across thousands of equities, helping me cross-check technical setups and sentiment shifts alongside traditional fundamental work. It has become a regular part of how I monitor early-stage medical technology companies that are moving from development into commercialization.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDAI's RSI Indicator recovers from oversold territory
The RSI Oscillator for MDAI moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 18 of the 20 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 63 cases where MDAI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MDAI as a result. In 68 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for MDAI just turned positive on November 09, 2026. Looking at past instances where MDAI's MACD turned positive, the stock continued to rise in 34 of 49 cases over the following month. The odds of a continued upward trend are 69%.
Following a +3.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDAI advanced for three days, in 136 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
MDAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
MDAI moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MDAI crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for MDAI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-3.978) is normal, around the industry mean (4.142). P/E Ratio (-4.656) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.078) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. MDAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement